In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
Germany’s Boehringer Ingelheim has announced positive results from a Phase II trial of survodutide, a glucagon/GLP-1 receptor dual agonist. 26 February 2024
Biotechnology
US biotech BioCryst Pharmaceuticals has announced new analyses of real-world use of oral, once-daily Orladeyo (berotralstat). 26 February 2024
Pharmaceutical
Global biopharma R&D productivity rebounded in 2023, according to a new report. 26 February 2024
Pharmaceutical
Dame June Raine, chief executive of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), has today announced that she will be stepping down in the fall following five years in the role. 26 February 2024
Biotechnology
US hematology specialist Disc Medicine today announced the appointment of Pamela Stephenson as the company’s chief commercial officer. 26 February 2024
Pharmaceutical
Teva Pharmaceutical Industries has formed a partnership with Jiangsu Nhwa Pharmaceutical for the marketing and distribution in China of Teva’s Austedo (deutetrabenazine). 26 February 2024
Biotechnology
US biotech major Amgen has made clear its objectives in rare disease, the company’s newest therapeutic area pillar, to drive long-term growth. 26 February 2024
Biotechnology
Swiss cancer giant Roche has outlined detailed results from the Phase III OUtMATCH study of Xolair (omalizumab). 26 February 2024
Pharmaceutical
The European Federation of Pharmaceutical Industries and Associations (EFPIA), as part of a coalition of 35 large health stakeholder organizations, is expressing its shared concerns about the latest negotiations on the proposed Regulation on the European Health Data Space (EHDS). 26 February 2024
Generics
The European Free Trade Association (EFTA) aims to conclude a trade agreement with India "within weeks," with the four-nation bloc showing a steadfast commitment to seal the deal before the Asian country enters its election cycle. However, concerns persist over a clause that may delay access to generic drugs in India for up to six years. 26 February 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cefepime-taniborbactam. 26 February 2024
Biosimilars
Icelandic firm Alvotech and Israel’s Teva Pharmaceutical Industries on Friday announced that the US Food and Drug Administration (FDA) has approved Simlandi (adalimumab-ryvk) injection. 26 February 2024
Pharmaceutical
UK pharma major GSK today announced positive headline results from the pivotal EAGLE-1 Phase III trial for gepotidacin. 26 February 2024
Biotechnology
Last week saw UK pharma major AstraZeneca announce that the US Food and Drug Administration (FDA) has accept its biological license application (BLA) for datopotamab deruxtecan for the treatment of lung cancer and also release positive Phase III results for Tagrisso in lung cancer. The FDA also granted approval for US biotech Iovance’s Amtagvi as a treatment for advanced melanoma, and slapped a clinical trial hold on US drug developer RAPT Therapeutics’ study of zelnecirnon in atopic dermatitis. Also of note, Rigel Pharmaceuticals entered into a deal to acquire US rights to cancer drug Gavreto that were recently handed back to Blueprint Medicines by Swiss pharma giant Roche. 25 February 2024
Biotechnology
On Friday, the US Food and Drug Administration (FDA) announced its final decision to withdraw the marketing authorization of Swedish biotech Oncopeptides’ Pepaxto (melphalan flufenamide). 24 February 2024
Biotechnology
South Korean vaccine developer SK bioscience revealed on Friday that it has obtained prequalification (PQ) certification from the World Health Organization (WHO) for its typhoid conjugate vaccine (TCV), SKYTyphoid (project name NBP618). 24 February 2024
Biotechnology
US mRNA medicine company Moderna closed 13% higher on Thursday after surprising investors with its financial results. 23 February 2024
Biotechnology
Sino-American healthcare-focused venture capital firm ORI Capital has announced the final close of its second fund. 23 February 2024
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines and one biosimilar for approval at its February 2024 meeting. 23 February 2024
Biotechnology
Japan’s largest drugmaker Takeda decided to discontinue the development programs of its four oncology assets - Phase III asset modakafusp alfa (TAK-573) and three Phase I chimeric antigen receptor (CAR-T) assets: TAK-102, TAK-103 and TAK-940 - as part of a plan to align its focus on advancing allogeneic cell therapies. 23 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze